Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion

被引:27
作者
Jaruratanasirikul, Sutep [1 ]
Sudsai, Teeratad [1 ]
机构
[1] Prince Songkla Univ, Fac Med, Dept Med, Hat Yai 90110, Songkla, Thailand
关键词
carbapenems; pharmacokinetic; pharmacodynamic; beta-lactams; INTERMITTENT INFUSION; BOLUS INJECTION; INTENSIVE-CARE; MEROPENEM; PHARMACOKINETICS; CEFTAZIDIME; THERAPY; PLASMA; MODEL;
D O I
10.1093/jac/dkn543
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to compare the t > MICs of imipenem between administration by a 2 h infusion with a 0.5 h infusion. The study was a randomized three-way crossover in nine patients with ventilator-associated pneumonia. Each subject received imipenem in three regimens consecutively: (i) a 0.5 h infusion of 0.5 g every 6 h for 24 h; (ii) a 2 h infusion of 0.5 g every 6 h for 24 h; and (iii) a 2 h infusion of 1 g every 6 h for 24 h. Following the 0.5 h infusion of 0.5 g of imipenem, the percentages of the t > 4 x MICs of 4, 2 and 1 mg/L were 20.32 +/- 9.32%, 44.11 +/- 16.40% and 64.67 +/- 20.56% of a 6 h interval, respectively. For the 2 h infusion of 0.5 g of imipenem, the percentages of the t > 4 x MICs of 4, 2 and 1 mg/L were 17.71 +/- 19.27%, 53.75 +/- 19.30% and 76.54 +/- 17.36% of a 6 h interval, respectively. For the 2 h infusion of 1 g of imipenem, the percentages of the t > 4 x MICs of 4, 2 and 1 mg/L were 60.26 +/- 23.96%, 77.78 +/- 20.11% and 93.35 +/- 8.26% of a 6 h interval, respectively. The 2 h infusions of imipenem resulted in greater t > MICs than the 0.5 h infusion. For infections caused by pathogens with high MICs, a 2 h infusion of 1 g of imipenem every 6 h can provide plasma concentrations above the MIC of 4 mg/L for 60% of a 6 h interval.
引用
收藏
页码:560 / 563
页数:4
相关论文
共 19 条
[11]   Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection [J].
Jaruratanasirikul, S ;
Sriwiriyajan, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) :518-521
[12]   Continuous infusion ceftazidime in intensive care: a randomized controlled trial [J].
Lipman, J ;
Gomersall, CD ;
Gin, T ;
Joynt, GM ;
Young, RJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (02) :309-311
[13]   KILLING OF PSEUDOMONAS-AERUGINOSA DURING CONTINUOUS AND INTERMITTENT INFUSION OF CEFTAZIDIME IN AN IN-VITRO PHARMACOKINETIC MODEL [J].
MOUTON, JW ;
DENHOLLANDER, JG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) :931-936
[14]  
Nicolau D, 1992, Conn Med, V56, P561
[15]  
Norrby SR, 1997, INFECT DIS CLIN PRAC, V6, P291
[16]   Two decades of imipenem therapy [J].
Rodloff, A. C. ;
Goldstein, E. J. C. ;
Torres, A. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (05) :916-929
[17]   Pharmacodynamics of cefepime in patients with Gram-negative infections [J].
Tam, VH ;
McKinnon, PS ;
Akins, RL ;
Rybak, MJ ;
Drusano, GL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (03) :425-428
[18]   Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units) [J].
Viaene, E ;
Chanteux, H ;
Servais, H ;
Mingeot-Leclercq, MP ;
Tulkens, PM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2327-2332
[19]   CORRELATION OF ANTIMICROBIAL PHARMACOKINETIC PARAMETERS WITH THERAPEUTIC EFFICACY IN AN ANIMAL-MODEL [J].
VOGELMAN, B ;
GUDMUNDSSON, S ;
LEGGETT, J ;
TURNIDGE, J ;
EBERT, S ;
CRAIG, WA .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (04) :831-847